Jan Handrick Beumer
Molecular Therapeutics/Drug Discovery Program
University of Pittsburgh Cancer Institute
Hillman Research Pavilion
Room G27D
USA
Name/email consistency: high
- Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Beumer, J.H., Eiseman, J.L., Gilbert, J.A., Holleran, J.L., Yellow-Duke, A.E., Clausen, D.M., D'Argenio, D.Z., Ames, M.M., Hershberger, P.A., Parise, R.A., Bai, L., Covey, J.M., Egorin, M.J. Cancer Chemother. Pharmacol. (2011)
- Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Beumer, J.H., Franke, N.E., Tolboom, R., Buckle, T., Rosing, H., Lopez-Lazaro, L., Schellens, J.H., Beijnen, J.H., van Tellingen, O. Invest. New. Drugs (2010)
- Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). Beumer, J.H., Lopez-Lazaro, L., Schellens, J.H., Beijnen, J.H., van Tellingen, O. Curr. Clin. Pharmacol (2009)
- Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Beumer, J.H., Eiseman, J.L., Parise, R.A., Joseph, E., Covey, J.M., Egorin, M.J. Clin. Cancer Res. (2008)
- Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Beumer, J.H., Parise, R.A., Newman, E.M., Doroshow, J.H., Synold, T.W., Lenz, H.J., Egorin, M.J. Cancer Chemother. Pharmacol. (2008)
- Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Beumer, J.H., Eiseman, J.L., Parise, R.A., Florian, J.A., Joseph, E., D'Argenio, D.Z., Parker, R.S., Kay, B., Covey, J.M., Egorin, M.J. Cancer Chemother. Pharmacol. (2008)
- Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Beumer, J.H., Garner, R.C., Cohen, M.B., Galbraith, S., Duncan, G.F., Griffin, T., Beijnen, J.H., Schellens, J.H. Invest. New. Drugs (2007)
- Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Beumer, J.H., Rademaker-Lakhai, J.M., Rosing, H., Hillebrand, M.J., Bosch, T.M., Lopez-Lazaro, L., Schellens, J.H., Beijnen, J.H. Cancer Chemother. Pharmacol. (2007)
- A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice. Beumer, J.H., Joseph, E., Egorin, M.J., Parker, R.S., D'argenio, D.Z., Covey, J.M., Eiseman, J.L. Clin. Cancer Res. (2006)
- Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection. Beumer, J.H., Joseph, E., Egorin, M.J., Covey, J.M., Eiseman, J.L. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2006)
- Mass balance studies, with a focus on anticancer drugs. Beumer, J.H., Beijnen, J.H., Schellens, J.H. Clin. Pharmacokinet (2006)
- Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. Beumer, J.H., Natale, J.J., Lagattuta, T.F., Raptis, A., Egorin, M.J. Pharmacotherapy (2006)
- Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice. Beumer, J.H., Eiseman, J.L., Parise, R.A., Joseph, E., Holleran, J.L., Covey, J.M., Egorin, M.J. Clin. Cancer Res. (2006)
- Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients. Beumer, J.H., Hillebrand, M.J., Pluim, D., Rosing, H., Foley, K., Yule, S.M., Schellens, J.H., Beijnen, J.H. Invest. New. Drugs (2005)
- Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Beumer, J.H., Rademaker-Lakhai, J.M., Rosing, H., Lopez-Lazaro, L., Beijnen, J.H., Schellens, J.H. Invest. New. Drugs (2005)